India’s Expanded Trial Waiver Proposal Sets R&D Site Inspection Clause

India has proposed expanding its clinical trial waiver clause to permit such exemption for drugs already approved in ICH countries, subject to certain conditions – a move which potentially augurs well for applicant firms and could improve patient access to some critical medicines.

Clinical trial

More from India

More from Asia